

Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_78563
Title of the Manuscript:	DRAMATIC RESPONSE OF DPP4 INHIBITORS IN PATIENTS OF COVID – 19 TRIGGERED UNCONTROLLED TYPE 2 DM – A CASE REPORT
Type of the Article	Case study

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

<https://www.journalpri.com/index.php/JPRI/editorial-policy>

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments		
Minor REVISION comments	Page 4, line 1 from the top: Use SARS CoV 2 virus instead of 'SARS COVID 19 virus' Page 4, line 4 from the top: Use Interleukin 6 which are responsible instead of 'Interleukin 6 are responsible' Page 4, Fig. 1: Please explain IR Page 4, Line 8 from the bottom: Use after she was instead of 'after he was'	
Optional/General comments	Please explain abbreviations e.g., DPP4, GLP Please write the references in the same way	

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	Daniela Vrinceanu
Department, University & Country	Carol Davila University of Medicine and Pharmacy, Romania